Gastric cancer (GC) is one of the most common malignant diseases and the second leading cause of cancer-related deaths worldwide. 1 Despite improved surgical techniques and chemotherapy, the overall survival of patients with GC remains unsatisfactory. 2 A better understanding of the initiation, invasion, and metastasis of GC is required to improve its clinical outcome. Using high-throughput sequencing, several genes with prognostic values have been studied extensively. 3-5 However, these targets have been rarely applied for clinical diagnosis or therapeutic use due to the limited understanding of their functions in the tumorigenesis of GC.
prognostic values in several forms of cancer. 6, 13 Latest evidence on tumorigenesis has revealed that lncRNAs play a vital role in the tumorigenesis of many forms of cancers, 6, 13 and several oncogenic lncRNAs, such as NEAT1, 7, 14 MALAT1 15, 16 and PVT1, 17 are well established. In addition, certain other lncRNAs, such as GAS5 18 and ZFAS1, 19 have been shown to act as tumour suppressors during carcinogenesis.
AFDN divergent transcript (AFDN-DT), also known as MLLT4 antisense RNA 1 (MLLT4-AS1), is an lncRNA located upstream of the Afadin (AFDN) gene. 20 AFDN, otherwise known as MLLT4 and AF6, has been identified as a fusion partner in Lysine Methyltransferase 2A gene (KMT2A). 21 In our previous study, we showed that high levels of AFDN-DT, but not AFDN, correlated with a favourable outcome in patients with GC 20 and suggested that AFDN-DT might be tumour suppressor, even though the mechanism of AFDN-DT in GC remains completely unknown.
In the present study, we revealed that AFDN-DT inhibits cell growth and invasion of GC cells. Moreover, RNA pull-down experiments and RNA-seq analysis revealed that AFDN-DT directly interacts with transcription factors and histones, and it is involved in transcriptional regulation. Moreover, we demonstrated that DNA hypermethylation is mainly responsible for the repressed expression of AFDN-DT, and treatment with DNA methylation inhibitors restored the expression of AFDN-DT.
| MATERIAL S AND ME THODS

| Cell line and lentiviral transfection
HGC27 cell line was purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences and cultured in RPMI 1640 (Hyclone) supplemented with 10% foetal bovine serum (FBS) (Biological Industries). The full-length mRNA of AFDN-DT was cloned into the Lenti-CMV vector, and the lentivirus was produced as previously described. 22 The lentivirus exhibiting AFDN-DT overexpression was transfected into HGC27 cells, and the positively transduced cells were selected using puromycin.
Cell growth was determined with the Cell Counting Kit-8 (CCK-8) (Dojindo) using the Multiskan FC Microplate spectrophotometer at OD450.
| Quantitative reverse transcription PCR (RT-qPCR)
Total RNA was extracted using TRIzol reagent (Life Technologies) 
| Animal models
Twenty male BALB/c-nu/nu mice (Shanghai SLAC Laboratory Animal Co., Ltd.) aged 6 weeks, were divided into two groups and were subcutaneously injected with 1 × 10 7 AFDN-DT or vector-transfected HGC27 cells. The tumour volume was assessed 18 days after injection. All the mice were euthanized on day 34, and the tumour weight was evaluated.
| Wound healing assay
AFDN-DT or vector transduced HGC27 cells (5 × 10 5 cells/well) were seeded into 6-well plates (Corning). Wounds were made by scratching the adherent cells on the plate with a sterile 200 μl pipette tip (12 hours after seeding), replaced with fresh culture medium and then cultured for 24 hours. The migration ability was evaluated by analysing the migration of the cells into the wounded area.
| Transwell migration assay
Cell migration was determined using the transwell membranes (Corning). Briefly, the upper transwell chamber was coated with 60 μL of Matrigel (BD) for 2 hours prior to the invasion assays.
AFDN-DT or vector transduced HGC27 cells (2 × 10 5 cells/well) in serum-free RPMI 1640 were seeded into the upper transwell chamber, and 600 μL of RPMI 1640 medium supplemented with 10% FBS was added to the lower chamber. After incubation for 24 hours, the cells that adhered to the upper surface of the membrane were removed. Meanwhile, the invaded or migrated cells, which adhered to the lower surface, were stained with 0.1% crystal violet and measured by optical microscopy. 
| RNA pull-down experiments
| RNA sequencing
RNA was extracted using TRIzol reagent (Life Technologies) according to the manufacturer's instructions. The RNA-seq library was constructed using the VAHTS mRNA-seq V2 Library Prep Kit for Illumina® (NR601, Vazyme) according to the manufacturer's instructions. The sequencing was performed using Illumina's Novaseq platform according to manufacturer's instruction. The raw RNA-seq data have been deposited at the GEO database (GSE139326).
| Chromatin isolation by RNA purification (ChIRP)
ChIRP was performed as previously described. 23 The AFDN-DT transduced HGC27 cells were fixed with 1% formaldehyde for 
| Bioinformatics analysis
All the sequenced reads were mapped to the hg38 genome using HISAT2, 24 and the sequence alignment mapping (SAM) files were sorted using samtools. 25 The expression of the genes was quantified using the htseq-count, 26 and the differentially expressed genes were identified using the DEseq2. 27 Gene ontology analysis was performed using the DAVID Functional Annotation Bioinformatics Microarray Analysis database. Motif enrichment analysis was performed using the MEME suite. 28 
| DNA methylation analysis
Information on DNA methylation and mRNA expression in the gastric tumour samples was obtained from TCGA cohort. 29 
| Treatment with DNA methylation inhibitor
HGC27 cells were treated with or without the DNA methylation inhibitor, decitabine, at a final concentration of 5 μmol/L for 24 hours. 
| Statistical analysis
All experiments were independently performed in triplicate. GraphPad Prism 7.0a was used for the statistical analyses. Data are presented as the mean ± SD. Statistical significance was determined using Student's t test. A P-value < .05 indicated statistical significance.
| RE SULTS
| Inhibition of cell growth and invasion of GC cells by AFDN-DT in vitro
To determine the function of AFDN-DT in GC, we firstly overexpressed AFDN-DT in HGC27 cells derived from a patient with GC and found that overexpression of the AFDN-DT inhibits the growth of the HGC27 cells ( Figure 1A ). Next, cell cycle analysis revealed that overexpression of AFDN-DT induces G0/G1 cell cycle arrest in HGC27 cells, indicating a potential function of AFDN-DT in cell growth regulation. We then performed wound healing experiments on the cells with or without AFDN-DT overexpression and found that the migration ability was significantly decreased upon AFDN-DT overexpression ( Figure 1B) . Further, we performed transwell invasion assays to determine the effect of AFDN-DT on the metastasis. As shown in Figure 1C 
| Interaction of AFDN-DT with histone proteins in GC cells
Next, to determine the mechanism underlying AFDN-DT-mediated growth and metastasis inhibition, we first determined the distribution of AFDN-DT lncRNA in the cytoplasm and nucleus. We found that AFDN-DT was mainly expressed in the nucleus, suggesting its potential function in transcriptional regulation ( Figure 3A ). Next, we performed an RNA pull-down assay coupled with LC-MS/MS to determine the interactome of AFDN-DT in the HGC27 cells. As shown in Figure 3B , silver-staining results of the proteins pulled down by AFDN-DT suggested that AFDN-DT can specifically bind to certain proteins. Moreover, the LC-MS/MS results revealed 14 proteins that could directly interact with AFDN-DT with high confidence ( Figure 3C ).
We found that these target proteins were mainly involved in nucleosome organizations, such as HIST1H4A, HIST1H1C, HIST1H2BK and H3F3C. Notably, the identified targets were core histone proteins, suggesting the possible transcriptional regulatory function of AFDN-DT in GC, and this needs to be explored in future studies.
| Involvement of AFDN-DT in transcriptional regulation through directly binding to the regulatory regions
To investigate the direct targets of transcription regulation by AFDN-DT, we performed the ChIRP using biotinylated antisense DNA probe sets ( Figure 4A ). We identified 9162 AFDN-DT targets that directly bind to regions on the chromatin (Table S1 ). Of these regions, 29% were promoters, whereas 44.8% were regions on the Figure 4B ). Next, we performed motif enrichment analysis of these regions and found that the motifs, SP1, NHLH and KLF13, were significantly enriched ( Figure 4C ), suggesting that AFDN-DT might affect the transcriptional function of these factors by regulating gene expression. As shown in Figure 4D 
| Involvement of AFDN-DT regulated genes in transcriptional regulation
To further understand the effects of AFDN-DT on transcriptional regulation, we performed RNA-seq experiments in HGC27 cells with or without AFDN-DT overexpression ( Figure 5A and Table S2 ).
Following this experiment, we overlapped the genes that were differentially expressed in cells with AFDN-DT overexpression, and the directly bound genes were identified using ChIRP-seq. We identified 415 genes that were directly regulated by AFDN-DT ( Figure 5B-C and Table S3 ). EGR1, FOS and JUN and their corresponding proteins were all down-regulated by overexpression of AFDN-DT ( Figure 5C ).
This observation was further validated by RT-qPCR using HGC27
cells with or without AFDN-DT overexpression ( Figure 5D ). Furthermore, the gene ontology analysis revealed that the genes directly regulated by AFDN-DT were mainly involved in transcriptional regulation (Table S4 ).
| Repression of AFDN-DT by DNA hypermethylation in GC
To determine the mechanism underlying the deregulation of AFDN-DT in GC, We analysed DNA methylation, which is an inheritable epigenetic modification, of the AFDN-DT gene in patients with GC from TCGA cohorts. 29 We found that the DNA methylation of AFDN-DT negatively correlated with AFDN-DT expression in the patients ( Figure 6A ). To confirm the direct link between AFDN-DT DNA methylation and AFDN-DT expression, we treated HGC27 cell lines with decitabine, a DNA methylation inhibitor, for 24 hours.
Subsequently, we found that its expression was significantly restored upon inhibition of DNA methylation and the growth of HGC27 cells was significantly repressed ( Figure 6B-D) . Taken together, these observations showed the mechanism underlying the down-regulation of AFDN-DT in GC. Our previous studies demonstrated that AFDN-DT was down-regulated in GC, and this was associated with poor prognosis in patients with GC. 20 However, we were unable to elucidate the function and mechanisms of AFDN-DT in GC. In addition, a study showed that the expression of AFDN-DT decreases in oral squamous cell carcinoma samples compared to the healthy oral mucosal cells. 30 Here, we demonstrated that AFDN-DT exerts tumour suppressive function in GC using both in vitro and in vivo models.
| D ISCUSS I ON
LncRNAs are regulators involved in multiple biological processes, 6, 8 including microRNA sponging, 9 translational 10 and transcriptional regulation 11 and protein-protein interactions. 12 Recent studies on the function of lncRNAs have revealed the direct histone binding and transcriptional regulation functions of lncRNAs. For instance, MALAT1, which is an lncRNA, directly interacts with DBC1 and P53 and regulates the acetylation of P53 protein. 31 Here, we demonstrated that AFDN-DT also interacts with core histone proteins and directly binds to the transcriptional regulatory regions of the genes essential for malignant transformation, such as FOS, JUN and EGR1, which encode three of the most widely known transcriptional factors in cancer. The FOS and JUN belong to the AP-1 transcriptional complex and have been reported to regulate the malignant transformation in GC. 32, 33 We found that the AFDN-DT overexpression down-regulated the expression of FOS and JUN, indicating that AFDN-DT directly inhibits the oncogenes in GC, and this further validates its tumour suppressive function.
Dysregulation of DNA methylation considerably influences gene expression, often resulting in malignant transformation. 34 Many studies on genes coding for tumour suppressive proteins as well as microRNAs have established that DNA hypermethylation contributes to tumour suppression, which eventually leads to carcinogenesis in gastric tissues. 35, 36 Here, we reported that DNA hypermethylation of the AFDN-DT promoter down-regulated the expression of AFDN-DT in the tumour samples. Furthermore, we found that demethylation by decitabine increased the expression of AFDN-DT. However, it is also possible that decitabine-induced inhibition of cell growth might be due to the restored expression of other tumour suppressor genes. Therefore, the role of the AFDN-DT-mediated regulation network and its association 
